Faes Farma, S.a. · BME:FAE
Faes Farma — Investor Day (March 2022)
40 slides from Faes Farma's investor day presentation, Mar 22, 2022
Slide 1: Looking at the future
Looking at the future Capital Markets Day 2022 March 22nd 2022
Slide 2: Key year, Future growth strategy, Sustainable horizon
2021 Future growth strategy Sustainable horizon: Key year Faes Farma´s value proposition 2
Slide 3: 2021: Exceeding expectations in a key year
2021: Exceeding expectations in a key year Guidance 20212 Final results 2021 Net Single digit growth 399M€ Sales1 vs. 2020 (380M€) +5% Between 87M€ - 91M€ 94M€ PBT Profit before tax vs. 2020 (85M€) +11% Notes: (1) Net sales refer to sales excluding other income; (2) Guidance for 2021 shared during t
Slide 4: Track record of 10 years of profitable growth
Track record of 10 years of profitable growth … Total Revenue PBT Variance 2011-2021 Variance 2011-2021 x 2,2 x 7,7 +8% CAGR +23% CAGR 195M€ 12M€ 2011 2021 2011 2021 4
Slide 5: In 2021 we overcame the greatest challenges of the last 10 years
In 2021 we have successfully overcome the greatest challenges of the last 10 years, Bilastine in Spain and over stock post Covid-19 Total Revenue [2020-2021, M€] Two challenges But we have been able to successfully overcome them marked 2021… through growth in the rest of our business End of the Over
Slide 6: Growth of Faes LATAM, Calcifediol in Spain and licenses
… leveraging on the strong growth of Faes LATAM, Calcifediol in Spain and licenses of other products Faes Calcifediol Licenses Calcifediol LATAM In Spain & Mesalazine Revenue 2021 vs. 2020 Revenue 2021 vs. 2020 Revenue 2021 vs. 2020 +66% +31% +139% +23,5M€ +7,4M€ +8,5M€ +4,4M€ +3,5M€ +1M€ Revenue EB
Slide 7: A. Strategy Pharma
2021 Future growth strategy Sustainable horizon: Key year Faes Farma´s value proposition A. Strategy Pharma B. Strategy Animal Nutrition & Health C. Industrial Projects 7
Slide 8: Our growth strategy in Pharma is based on three pillars
Our growth strategy in Pharma is based on three pillars I II III Renewed and Growing our strategic Adding value to our determined product lines direct sales model commitment to research 8
Slide 9: Pillar I: Growth related to our strategic product lines
I Strategic product lines Pillar I: Growth related to our strategic product lines based on innovation and internationalization Bilastine Calcifediol Mesalazine … to further develop our strategic product portfolio Innovation… … combining direct sales with a licensing strategy which uses International
Slide 10: Bilastine, a leading antihistamine with a great future ahead
I Strategic product lines | Bilastine Bilastine, a leading antihistamine with a great future ahead 95M€ Bilastine revenue will continue to grow beyond 2022 Total revenue Bilastine in 2021 Launches in the short-medium Best-selling antihistamine in term in two3 of the six main markets 4 prescription m
Slide 11: Leadership position in main markets with geographical expansion
I Strategic product lines | Bilastine We have a leadership position in the main markets, with an outlook of further geographical expansion Top antihistamine markets Faes Farma and presence of Bilastine [R6A1, 2021, M€] Growth Bilastine +18% in volume / Japan Bilastine 16%2 819 Bilastine +13% in valu
Slide 12: We continue to develop the Bilastine franchise through innovation
I Strategic product lines | Bilastine At the same time, we continue to develop the franchise through innovation Antihistamine market size[M€, 2021] Portfolio and pipeline of the Bilastine franchise # Year of first launch Pediatric 2026 Bilastine + 2027 Bilastine + 2025 Decongestants1 268 Decongestan
Slide 13: Calcifediol will continue to sustain strong growth
I Strategic product lines| Calcifediol Calcifediol, with greater efficacy in the treatment of pro-hormone D deficiency, will continue to sustain strong growth in the future Calcifediol will continue to grow in current markets 42M€ and through new launches Total revenue of Calcifediol in 2021 Strong
Slide 14: Leading position in main markets, growth via upcoming launches
I Strategic product lines| Calcifediol We have a leading position in our main markets, and we will continue to grow via upcoming launches Faes Farma top markets for vitamin D and presence of Calcifediol1 [2021, M€] Brazil 256 License signed in 2021 Italy Calcifediol Faes Farma 2,2%2 202 Growth Calci
Slide 15: Developing a portfolio of forms of greater efficacy and combinations
I Strategic product lines| Calcifediol We are developing a portfolio of forms of greater efficacy and in combination for the treatment with pro-hormone D Portfolio and pipeline of the Calcifediol franchise # Year of first launch Extension of the Increased indications diagnostic proving the capacity
Slide 16: Mesalazine, baseline treatment for ulcerative colitis
I Strategic product lines | Mesalazine Mesalazine, baseline treatment for mild-moderate ulcerative colitis with multiple launches planned Mesalazine will continue to grow to have the widest range of formulations for this molecule 900M€ Total global market of Mesalazine Development of the most comple
Slide 17: Expanding geographic footprint for Mesalazine
I Strategic product lines | Mesalazine In addition, we are expanding our geographic footprint in key markets and strengthening our position Top Faes Farma markets for Mesalazine and presence of Mesalazine Faes Farma1 [2021, M€] UK 116 Expected launch in 2022 Germany Mesalazine FF 5,5%2 106 Launched
Slide 18: Developing the most complete range of Mesalazine
I Strategic product lines | Mesalazine We are also developing the most complete range of Mesalazine Ulcerative Colitis Treatment Market Size [M€] Portfolio and pipeline of the Mesalazine franchise # Year of first launch + Amplified granule range + Granules 216 2027 innovative technology Current form
Slide 19: Strategic product lines still pending launch in markets worth >€1,700M
I Strategic product lines Our strategic product lines are still pending launch in markets with a value of >€1,700M Bilastine1 Calcifediol2 Mesalazine3 Market size of Current markets current sales presence Faes Farma ~2.630M€ ~600M€ ~280M€ ~3.500M€ New Size of markets where markets (5 years) there is
Slide 20: Pillar II: Adding value to our direct sales model
II Direct sales model Pillar II: Adding value to our direct sales model Consolidated Dynamic and business… growing market … Pharma … with less Faes Spain …flexible & resilient… regulatory LATAM pressure… … with high portfolio … and synergistic renewal capacity with our core business 20
Slide 21: Pharma business in Spain is a resilient and flexible engine
II Direct sales model Our Pharma business in Spain is one of our great engines, highly resilient and flexible Characteristics Evolution Outlook A consolidated business… Proven portfolio strength and renewal New launches planned, to renew capacity the portfolio: 153M€ in revenue 1 Evolution of total
Slide 22: Growing Bilastine share despite generics entering Spain
II Direct sales model In 2021 we have faced our greatest challenge, managing to grow in share with Bilastine despite the entry of generics in Spain Antihistamine market in Spain [2018-2022E, Million units sold] Entrance generics Bilastine (06/2021) 1 • 06/2021: end of patent of 27 Bilastine in Spain
Slide 23: Reinforcing direct sales business in LATAM
II Direct sales model Likewise, we are reinforcing our direct sales business in LATAM, where we have strong growth prospects Characteristics Evolution Outlook • Presence in 6 of the main LATAM • Expected sales growth at markets x6 in revenues in the past 5 double digit in • Dynamic and growing marke
Slide 24: Aspiring to become a Top 25 pharma player in LATAM markets
II Direct sales model We aspire to become one of the Top 25 pharma players in our LATAM markets Evolution of total subsidiary revenues Faes LATAM [M€] Objetive 2025: be part of Top 25 pharmaceuticals in our markets1 and continue to improve EBITDA towards 20% in 2025 2020 2021 +19%2 20,4 17,1 The acq
Slide 25: Pillar III: Renewed commitment to research
III Commitment to research Pillar III: Renewed and determined commitment to research to continue guaranteeing our long-term value Prioritization of strategic therapeutic areas We are reinforcing the R&D department, making a Strengthening our renewed commitment to pipeline for the future research Tra
Slide 26: Applied research on our strategic therapeutic areas
III Commitment to research We are employing applied research (drug discovery) on our strategic therapeutic areas Strategic therapeutic areas Our therapeutic areas are aligned with the company's long-term strategy, and share three key criteria: • Rising prevalence… Targeting a growing market • … with
Slide 27: Strengthening our drug discovery pipeline
III Commitment to research We continue to strengthen our drug discovery pipeline in our strategic therapeutic areas Therapeutic Area Project Research Pipeline Stage Current status of the project 1 Early Discovery 2 Screening 3 Optimization 4 Pre-regulatory Chronic Urticaria FAE4URT • ~ 1 year to ent
Slide 28: Transforming our applied research department
III Commitment to research We are transforming our applied research department (drug discovery) Integration in the Increased Recruitment of Flexibility scientific investments external talent ecosystem Progressive increase in investment • Constant monitoring and By recruiting top-level Integration vi
Slide 29: B. Strategy Animal Nutrition & Health
2021 Future growth strategy Sustainable horizon: Key year Faes Farma´s value proposition A. Strategy Pharma B. Strategy Animal Nutrition & Health C. Industrial Projects 29
Slide 30: Leaders in the Animal Nutrition and Health sector
We are leaders in the Animal Nutrition and Health sector, in a segment with high added value and high profitability Farm Faes Business Vision Growth levers in the medium term Leader in early age porcine Strengthening of the solid position in nutrition. Highly technological and value-added product, a
Slide 31: C. Industrial Projects
2021 Future growth strategy Sustainable horizon: Key year Faes Farma´s value proposition A. Strategy Pharma B. Strategy Animal Nutrition & Health C. Industrial Projects 31
Slide 32: Reinforcing industrial capacities at Farm Faes
At Farm Faes, we are reinforcing our industrial capacities to be able to fully manufacture specialty foods for early ages We will invest €17M in a new manufacturing plant for specialty foods for early ages. This strategic decision, which involves vertical integration in the value chain, will lead to
Slide 33: Investing in a new industrial plant for Pharma growth
We are investing in an ambitious industrial project to accommodate the growth of the Pharma business We are in the process of building a new manufacturing plant, with an estimated investment of >€160M, which will triple our production capacity and allow us to meet our strategic growth plans Capacity
Slide 34: Guidance 2022, ESG, Value Proposition
2021 Future growth strategy Sustainable horizon: Key year Faes Farma´s value proposition A. Guidance 2022 B. ESG Commitment C. Faes Farma´s Value Proposition 34
Slide 35: In 2022 we will continue to grow strongly
Faes Farma´s Value Proposition | A. Guidance 2022 In 2022, we will continue to grow strongly and create shareholder value Bilastine Licenses ▲ Revenues Recovery of order volumen in Net Growth of ~8% vs. 2021 > 10% Japan: Growth in top and bottom line Sales1 2021: 399M€ 2022E: 422M€ - 437M€ Licenses
Slide 36: Solid commitment to environmental, social and governance objectives
Faes Farma´s Value Proposition | B. ESG Commitment At Faes Farma, we have a solid commitment to integrating environmental, social and governance objectives Faes Farma: ESG value and strategic pillars ESG Milestones 2021 Faes Farma Aligning our strategic objectives with the Sustainable Development Go
Slide 37: What makes Faes Farma a secure value for investors?
Faes Farma´s Value Proposition | C. Value Proposition What makes Faes Farma a secure value for investors? High growth potential of our strategic product lines, with a bright future ahead in terms of range development and entry into new markets Reinforced commitment to the R&D department, redoubling
Slide 38: Q&A
Q&A Q&A iF Facs ranma 38
Slide 39: Looking at the future
| FAGS FARMA Looking at the future
Slide 40: Disclaimer
Disclaimer This presentation has been prepared and published by Faes Farma Group and is presented for informational purposes only. This presentation is not a brochure, nor is it an offer or recommendation to make an investment. This presentation does not imply any subscription commitment, nor an off